Hongbo Lu Sells 2,970 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director directly owned 52,012 shares in the company, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arrowhead Pharmaceuticals Stock Down 3.8%

ARWR stock opened at $76.67 on Friday. The firm has a market cap of $10.80 billion, a PE ratio of -35.66 and a beta of 1.28. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The firm’s 50 day moving average price is $65.94 and its 200-day moving average price is $61.85. Arrowhead Pharmaceuticals, Inc. has a one year low of $14.30 and a one year high of $82.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.17. The firm had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The business’s revenue for the quarter was down 86.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.75 EPS. On average, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.94 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ARWR shares. B. Riley Financial lifted their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. JPMorgan Chase & Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They set an “overweight” rating and a $88.00 price target on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, May 6th. Sanford C. Bernstein boosted their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.80.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and $100 price target on Arrowhead Pharmaceuticals, while also lifting its FY2026 earnings estimate, reinforcing a bullish long-term view on the company’s RNAi pipeline.
• Positive Sentiment: Other recent analyst actions remain constructive, including Royal Bank of Canada raising its price target to $87, JPMorgan starting coverage with an Overweight rating, and Sanford C. Bernstein boosting its target to $46.
• Neutral Sentiment: Arrowhead presented at the Bank of America Global Healthcare Conference, but the headline does not indicate a major new clinical or financial update that would materially change near-term expectations. Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: HC Wainwright made only small mixed tweaks to its 2026-2027 EPS forecasts, suggesting the analyst still sees the bigger story as intact despite minor quarter-to-quarter changes.
• Negative Sentiment: Director Hongbo Lu sold 2,970 shares in a pre-arranged 10b5-1 transaction. The sale was modest relative to his remaining stake, but insider selling can still be viewed cautiously by investors.
• Negative Sentiment: Arrowhead’s latest quarterly results showed a large year-over-year revenue decline and continued losses, reminding investors that the company remains unprofitable and dependent on future pipeline progress.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tsfg LLC purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $25,000. First Horizon Corp purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $32,000. WPG Advisers LLC raised its position in Arrowhead Pharmaceuticals by 384.8% in the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 431 shares during the period. Hantz Financial Services Inc. raised its position in Arrowhead Pharmaceuticals by 177.1% in the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 471 shares during the period. Finally, Elyxium Wealth LLC purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $54,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.